 |
|
Non-Hodgkin Lymphoma Trial Results
1. Study Suggests New Options for Follicular Lymphoma
(Posted: 10/30/2008) - Treatment with a radiolabeled monoclonal antibody appears to be highly effective as consolidation after first-line therapy in patients with indolent, advanced-stage follicular lymphoma, according to the October 14, 2008, Journal of Clinical Oncology.
2. Follicular Lymphoma Treatment Better With Rituximab
(Posted: 05/15/2005, Updated: 08/18/2008) - In patients with newly diagnosed follicular lymphoma, the addition of rituximab (Rituxan®) to the standard chemotherapy regimen CVP dramatically delayed the progression of disease, produced higher response rates that lasted longer, and extended survival compared to treatment with CVP alone, according to the July 28, 2008, Journal of Clinical Oncology.
3. Less-Intense Chemotherapy Benefits Some Children With B-Cell Non-Hodgkin Lymphoma
(Posted: 04/25/2007) - Children and adolescents with less advanced B-cell non-Hodgkin lymphoma did just as well, and suffered fewer side effects, when treated with lower doses of multi-drug chemotherapy than is called for by the current standard of care, according to the April 1, 2007, issue of the journal Blood.
4. Radiation Might be Avoided for Older Patients with Good Prognosis Non-Hodgkin's Lymphoma
(Posted: 02/14/2007) - Chemotherapy alone was just as effective as chemoradiotherapy in promoting survival among certain lymphoma patients over 60, suggesting that similar patients might be able to avoid the toxicity of radiation therapy, according to the March 1, 2007, Journal of Clinical Oncology.
5. Rituximab Helps Patients with Recurrent Lymphomas
(Posted: 10/26/2005, Updated: 11/01/2006) - Two studies from Germany showed the targeted therapy rituximab (Rituxan®) to be effective in treating recurrent or refractory follicular and mantle cell lymphomas. Findings from these studies were presented at the 2005 and 2006 annual meetings of the American Society of Clinical Oncology.
1 2 3 Next >
|
|
|
